Splash Beverage price target lowered to 50c from $1 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Splash Beverage (SBEV) to 50c from $1 and keeps a Buy rating on the shares following the Q3 report. The business stalled until new funding agreements are completed,
Regenxbio price target lowered to $36 from $40 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Regenxbio (RGNX) to $36 from $40 and keeps a Buy rating on the shares after the
Atmos Energy price target raised to $165 from $148 at Mizuho
Mizuho analyst Gabriel Moreen raised the firm’s price target on Atmos Energy (ATO) to $165 from $148 and keeps an Outperform rating on the
Alector price target lowered to $7 from $35 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating on the shares. The company announced that the Phase 2 INVOKE-2 trial, which evaluated the TREM2 antibody,
Iris Energy price target raised to $17 from $15 at Canaccord
Canaccord raised the firm’s price target on Iris Energy (IREN) to $17 from $15 and keeps a Buy rating on the shares. The firm said with one of the
Iris Energy price target raised to $16 from $13 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Iris Energy (IREN) to $16 from $13 and keeps a Buy rating on the shares. The company is
bovnews11h
What’s Causing Humacyte Inc (HUMA) Stock’s -40.24% Drop Over the Last Six Months?
On Friday, Humacyte Inc (HUMA) stock saw a modest uptick, ending the day at $4.47 which represents a slight increase of $0.07 or 1.59% from the prior close of $4.4. The stock opened at $4.44 and ...
CollPlant initial breast implant data ‘encouraging,’ says H.C. Wainwright
H.C. Wainwright maintains a Buy rating and 12-month price target of $11 on CollPlant (CLGN) shares after the company reported Q3 results and ...
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
To access the live webcast of the fireside chat, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a ...
bovnews1d
H.C. Wainwright Issues Buy Rating for Quantum-Si Inc (QSI) Stock
H.C. Wainwright has recently initiated Quantum-Si Inc (QSI) stock to Buy rating, as announced on December 8, 2023, according to Finviz. Earlier, on September 25, 2023, Canaccord Genuity had reduced ...
Arqit Quantum target adjusted to $22 from $2 at H.C. Wainwright
H.C. Wainwright adjusted the firm’s price target on Arqit Quantum (ARQQ) to $22 from $2 and keeps a Buy rating on the shares to reflect the ...
Nasdaq4d
Cassava Sciences downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Vernon Bernardino downgraded Cassava Sciences (SAVA) to Neutral from Buy without a price target after the company announced results from its ReThink-ALZ Phase 3 trial with ...
MyChesCo on MSN1d
Join Arbutus Biopharma for Virtual Fireside Chat!
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in the virtual H.C. Wainwright @ Home fireside chat ...
Bitcoin drifts down toward $90K; can it hit $100K by year-end?
Bitcoin (BTC-USD) pulled back from its historic high of $99.8K touched on Friday, drifting down to $91.9K Tuesday, triggering ...
Nasdaq5d
BridgeBio price target raised to $49 from $43 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $49 from $43 and keeps a Buy rating on the shares. Acoramidis received regulatory approval with the label underscoring ...
bovnews3d
H.C. Wainwright Just Downgraded Eyenovia Inc (EYEN) Stock—What Does This Mean for Investors?
H.C. Wainwright has recently reduced Eyenovia Inc (EYEN) stock to Neutral rating, as announced on November 18, 2024, according to Finviz. Earlier, on March 1, 2021, Northland Capital had initiated the ...